[1] Sly PD, Galbraith S, Islam Z, et al. Primary prevention of severe lower respiratory illnesses in at-risk infants using the immunomodulator OM-85[J]. J Allergy Clin Immunol, 2019,144(3):870-872.
[2] Marengo R, Ortega Martell JA, Esposito S. Paediatric recurrent ear, nose and throat infections and complications:Can we do more?[J]. Infect Dis Ther, 2020,9(2):275-290.
[3] Esposito S, Jones MH, Feleszko W, et al. Prevention of new respiratory episodes in children with recurrent respiratory infections: An expert consensus statement from the world association of infectious diseases and immunological disorders (WAidid)[J]. Microorganisms, 2020,8(11):1810-1810.
[4] Cantarutti A, Barbieri E, Scamarcia A, et al. Use of the bacterial lysate OM-85 in the paediatric population in Italy: A retrospective cohort study[J]. Int J Environ Res Public Health, 2021,18(13):6871.
[5] 陈莉娜, 刘瀚旻. 儿童反复呼吸道感染合理用药[J]. 中国实用儿科杂志, 2020,35(3):202-206.
[6] 中国医师协会儿科医师分会儿童耳鼻咽喉专业委员会. 儿童反复上呼吸道感染临床诊治管理专家共识[J]. 中国实用儿科杂志, 2017,32(10):721-725.
[7] 戎萍, 马融, 张喜莲, 等. 细菌溶解产物胶囊防治儿童反复呼吸道感染有效性和安全性的Meta分析[J]. 中国药房, 2018,29(12):1702-1706.
[8] Jurkiewicz D, Zielnik-Jurkiewicz B. Bacterial lysates in the prevention of respiratory tract infections[J]. Otolaryngol Pol, 2018,72(5):1-8.
[9] Esposito S, Bianchini S, Bosis S, et al. A randomized, placebo-controlled, double-blinded, single-centre, phase IV trial to assess the efficacy and safety of OM-85 in children suffering from recurrent respiratory tract infections[J]. J Transl Med, 2019,17(1):284.
[10] Esposito S, Bianchini S, Polinori I, et al. Impact of OM-85 given during two consecutive years to children with a history of recurrent respiratory tract infections: A retrospective study[J]. Int J Environ Res Public Health, 2019,16(6):1065.
[11] 中国医师协会儿科医师分会儿童耳鼻咽喉专业委员会. 儿童过敏性鼻炎诊疗—临床实践指南[J]. 中国实用儿科杂志, 2019, 34 (3):169-175.
[12] Bousquet J, Anto JM, Bachert C, et al. Allergic rhinitis[J]. Nat Rev Dis Primers, 2020,6(1):95.
[13] Blaiss MS, Hammerby E, Robinson S, et al. The burden of allergic rhinitis and allergic rhinoconjunctivitison adolescents[J]. Ann Allergy Asthma Immunol, 2018,121(1):43-52.
[14] Morjaria JB, Caruso M, Emma R, et al. Treatment of allergic rhinitis as a strategy for preventing asthma[J]. Curr Allergy Asthma Rep, 2018,18(4):23.
[15] 岳立文,曲红明,毛辰,等.南京市学龄前儿童呼吸道过敏性疾病与睡眠状况的现况研究[J]. 中国儿童保健杂志, 2016,24(12):1260-1262.
[16] Janeczek K, Emeryk A, Rachel M, et al. Polyvalent mechanical bacterial lysate administration improves the clinical course of grass pollen-induced allergic rhinitis in children: A randomized controlled trial[J]. J Allergy Clin Immunol Pract, 2021,9(1):453-462.
[17] Meng Q, Li P, Li Y,et al. Broncho-vaxom alleviates persistent allergic rhinitis in patients by improving Th1/Th2 cytokine balance of nasal mucosa.[J]. Rhinology, 2019,57(6):451-459.
[18] Banche G, Allizond V, Mandras N, et al. Improvement of clinical response in allergic rhinitis patients treated with an oral immunostimulating bacterial lysate: In vivo immunological effects[J]. Int J Immunopathol Pharmacol, 2007,20(1):129-138.
[19] Feleszko W, Rossi GA, Krenke R, et al. Immunoactive preparations and regulatory responses in the respiratory tract:Potential for clinical application in chronic inflammatory airway diseases[J]. Expert Rev Respir Med, 2020,14(6):603-619.
[20] Huang K, Yang T, Xu JY, et al. Prevalence, risk factors, and management of asthma in China: A national cross-sectional study[J]. Lancet, 2019,394(10196):407-418.
[21] 刘传合, 洪建国, 尚云晓, 等. 第三次中国城市儿童哮喘流行病学调查[J]. 中华儿科杂志, 2013,51(10):729-735.
[22] 中华儿科杂志编辑委员会, 中华医学会儿科学分会呼吸学组, 中国医师协会儿科医师分会儿童呼吸专业委员会. 儿童支气管哮喘规范化诊治建议(2020年版)[J]. 中华儿科杂志, 2020,58(09):708-717.
[23] Global Initiative for Asthma. Global strategy for asthma management and prevention, 2020[J/OL]. https://ginasthma.org/gina-reports/.
[24] Emeryk A, Bartkowiak-Emeryk M, Raus Z, et al. Mechanical bacterial lysate administration prevents exacerbation in allergic asthmatic children-The EOLIA study[J]. Pediatr Allergy Immunol, 2018,29(4):394-401.
[25] de Boer GM, Zolkiewicz J, Strzelec KP, et al. Bacterial lysate therapy for the prevention of wheezing episodes and asthma exacerbations: A systematic review and meta-analysis[J]. Eur Respir Rev, 2020,29(158):190175.
[26] 李京阳, 包军, 鲍一笑. 细菌溶解产物OM-85BV对儿童哮喘发作及其鼻部症状的疗效研究[J]. 儿科药学杂志, 2017,23(1):7-10.
[27] Lu YM, Li YQ, Xu LY, et al. Bacterial lysate increases the percentage of natural killer T cells in peripheral blood and alleviates asthma in children[J]. Pharmacology, 2015,95(3-4):139-144.
[28] Stern J, Pier J, Litoniua AA. Asthma epidemiology and risk factors[J]. Seminars in Immunopathology, 2020,42(1):5-15.
[29] Okyere DO, Bui DS, Washko GR, et al. Predictors of lung function trajectories in population-based studies: A systematic review[J]. Respirology, 2021,26(10):938-959.
[30] Jartti T, Gern JE. Role of viral infections in the development and exacerbation of asthma in children[J]. J Allergy Clin Immunol, 2017,140(4):895-906.
[31] Bacharier LB. Azithromycin during wheezing illnesses among preschool children: Does the airway microbiota provide insights into mechanism?[J]. Am J Respir Crit Care Med, 2021,204(2):115-116.
[32] Razi CH, Harmanci K, Abaci A, et al. The immunostimulant OM-85 BV prevents wheezing attacks in preschool children[J]. J Allergy Clin Immunol, 2010,126(4):763-769.
[33] Yin J, Xu BP, Zeng XT, et al. Broncho-Vaxom in pediatric recurrent respiratory tract infections: A systematic review and meta-analysis[J]. Int Immunopharmacol, 2018,54: 198-209.
[34] Rossi GA, Pohunek P, Feleszko W, et al. Viral infections and wheezing-asthma inception in childhood: Is there a role for immunomodulation by oral bacterial lysates?[J]. Clin Transl Allergy, 2020,10(1):17.
[35] Dang AT, Pasquali C, Ludigs K, et al. OM-85 is an immunomodulator of interferon-beta production and inflammasome activity[J]. Sci Rep, 2017,7(1):43844.
[36] Ross GA, Bessler W, Ballarini S, et al. Evidence that a primary anti-viral stimulation of the immune response by OM-85 reduces susceptibility to a secondary respiratory bacterial infection in mice[J]. Ital J Pediatr, 2018,44(1):112.
[37] Roth M, Pasquali C, Stolz D, et al. Broncho Vaxom (OM-85) modulates rhinovirus docking proteins on human airway epithelial cells via Erk1/2 mitogen activated protein kinase and cAMP[J]. PLoS One, 2017,12(11):e0188010.
[38] Ferrara F, Rial A, Suarez N, et al. Polyvalent bacterial lysate protects against pneumonia independently of neutrophils, IL-17A or Caspase-1 activation[J]. Front Immunol, 2021,12:562244.
[39] Esposito S, Soto-Martinez ME, Feleszko W, et al. Nonspecific immunomodulators for recurrent respiratory tract infections, wheezing and asthma in children: A systematic review of mechanistic and clinical evidence[J]. Curr Opin Allergy Clin Immunol, 2018,18(3):198-209.
[40] Liu YW, Dong SH, Zhan GY, et al. Analysis of the effect of bacterial lysate and the immunologic mechanism in treating infant bronchiolitis[J]. Eur Rev Med Pharmacol Sci, 2017,21(14):3332-3336.
[41] Bartkowiak-Emeryk M, Emeryk A, Rolinski J, et al. Impact of polyvalent mechanical bacterial lysate on lymphocyte number and activity in asthmatic children: A randomized controlled trial[J]. Allergy Asthma Clin Immunol, 2021,17(1):10.
[42] Liu C, Huang R, Yao RJ, et al. The immunotherapeutic role of bacterial lysates in a mouse model of asthma[J]. Lung, 2017,195(5):563-569.
[43] Han RF, Li HY, Wang JW, et al. Study on clinical effect and immunologic mechanism of infants capillary bronchitis secondary bronchial asthma treated with bacterial lysates Broncho-Vaxom[J]. Eur Rev Med Pharmacol Sci, 2016,20(10):2151-2155.